Professionals working in the field of Pharmacovigilance traditionally collect and assess reports of potential adverse events based on information received from healthcare providers’ interactions with patients. In addition, pharma companies are required to consider the information coming directly from consumer reports.
As social media use increases, so do the number of disease and therapeutic resource forums and communication threads. At the same time, pharmaceutical business is moving faster and vigilance legislation is getting tighter to regulate the safe use of medicine. It costs less for a company to perform pharmacovigilance than to pay the fine when not compliant. With this in mind, UBC research scientists sought to investigate the strength of Adverse Events identified via social media.